Key result
Methanolic extract of Centaurea borysthenica at 1 mg/mL significantly increased the viability of doxorubicin-treated cardiomyocytes from 54.32% to 89.4%.
Population
Embryonic rat cardiomyocytes H9C2 and human peripheral blood myeloma CCL-155 cells
Comparison
Methanolic extracts of Centaurea borysthenica… vs Doxorubicin 5 µM alone, media alone, and…
Design
Preclinical
Follow-up
24 hours
Authors
Loading...
Does not support clinical use of Centaurea extracts with doxorubicin; leaves open effects on anti-tumor efficacy.
Absolute Event Rate: 89.4% vs 54.32%
p-value: p=≤0.05
Methanolic extracts of Centaurea species protect cardiomyocytes from doxorubicin-induced toxicity in vitro, but C. borysthenica may compromise doxorubicin's anti-tumour efficacy.
Korga-Plewko et al. (2017) studied Doxorubicin-induced cardiotoxicity. Methanolic extracts of Centaurea borysthenica and Centaurea daghestanica vs. Doxorubicin alone (5 µM) was evaluated on Cardiomyocyte cell viability (p=≤0.05). Methanolic extract of Centaurea borysthenica at 1 mg/mL significantly increased the viability of doxorubicin-treated cardiomyocytes from 54.32% to 89.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: